<p>Olema Pharmaceuticals（纳斯达克代码：OLMA - 获取免费报告）的股票在周一发布的报告中被 HC Wainwright 的股票分析师重新给予了 “买入” 评级，Benzinga 报道。他们目前对该股票的目标价格为 30.00 美元。</p>
<p>获取 <strong>Olema Pharmaceuticals</strong> 的提醒：</p>
<p>其他一些分析师也对 OLMA 发表了看法。Oppenheimer 在 3 月 19 日的研究报告中重申了 “跑赢大盘” 的评级，并将 Olema Pharmaceuticals 的目标价格下调至 25.00 美元（之前为 30.00 美元）。摩根大通将 Olema Pharmaceuticals 的目标价格从 30.00 美元下调至 28.00 美元，并在 3 月 28 日的报告中对该公司设定了 “增持” 评级。</p>
<p><strong>查看我们对 OLMA 的最新分析</strong></p>
<h2>Olema Pharmaceuticals 股票下跌 3.7%</h2>
<p>纳斯达克：OLMA 周一开盘价为 4.91 美元。该公司的 50 日移动平均价格为 4.20 美元，200 日移动平均价格为 6.78 美元。Olema Pharmaceuticals 的 52 周最低价为 2.86 美元，52 周最高价为 16.62 美元。该股票的市值为 3.3552 亿美元，市盈率为-2.24，贝塔值为 2.10。</p>
<p>Olema Pharmaceuticals（纳斯达克代码：OLMA - 获取免费报告）最近在 3 月 18 日发布了季度财报。该公司报告每股收益（EPS）为-0.51 美元，超出分析师一致预期的-0.63 美元，超出幅度为 0.12 美元。整体来看，卖方分析师预计 Olema Pharmaceuticals 在本年度将发布-2.33 美元的每股收益。</p>
<h2>Olema Pharmaceuticals 的机构交易</h2>
<p>机构投资者最近增加或减少了对该股票的持股。摩根大通在第三季度将其在 Olema Pharmaceuticals 的持股比例提高了 658.7%。摩根大通目前拥有 181,032 股该公司的股票，价值 2,162,000 美元，此前在上个季度增持了 157,171 股。HighTower Advisors LLC 在第四季度收购了 Olema Pharmaceuticals 的新股份，价值 510,000 美元。Hennion &amp; Walsh 资产管理公司在第四季度将其在 Olema Pharmaceuticals 的持股比例提高了 80.5%。Hennion &amp; Walsh 资产管理公司目前拥有 212,246 股该公司的股票，价值 1,237,000 美元，此前在该期间增持了 94,651 股。Alliancebernstein L.P.在第四季度将其在 Olema Pharmaceuticals 的持股比例提高了 77.7%。Alliancebernstein L.P.目前拥有 313,982 股该公司的股票，价值 1,831,000 美元，此前在上个季度增持了 137,319 股。最后，巴克莱银行在第三季度将其在 Olema Pharmaceuticals 的持股比例提高了 105.0%。巴克莱银行目前拥有 94,915 股该公司的股票，价值 1,133,000 美元，此前在上个季度增持了 48,614 股。机构投资者和对冲基金持有该公司 91.78% 的股票。</p>
<h2>Olema Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>Olema Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，专注于女性癌症的治疗方法的发现、开发和商业化。其主要产品候选药物是 OP-1250，一种雌激素受体（ER）拮抗剂和选择性 ER 降解剂，目前正在进行针对复发性、局部晚期或转移性雌激素受体阳性、HER2 阴性乳腺癌的三期临床试验；以及 OP-1250 与 CDK4/6 抑制剂 palbociclib、ribociclib 和 alpelisib 联合进行的一期/二期临床试验，针对复发性、局部晚期或转移性雌激素受体阳性、HER2 阴性乳腺癌，同时开发 OPERA-01 用于 ER+/HER2-晚期或转移性乳腺癌的治疗。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Olema Pharmaceuticals 更好</li>
<li>最具波动性的股票，投资者需要知道的事项</li>
<li>熊市才刚刚开始 - 这是为什么</li>
<li>使用 MarketBeat 股息税计算器</li>
<li>这三只 ETF 让你在不需要金库的情况下持有真正的黄金</li>
<li>如何投资小盘股</li>
<li>为什么机构再次购买超微计算机股票</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Olema Pharmaceuticals 吗？</h2>
<p>在考虑 Olema Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Olema Pharmaceuticals 并不在名单上。</p>
<p>虽然 Olema Pharmaceuticals 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

OLMA

<p>HC Wainwright 重申了对 Olema Pharmaceuticals (NASDAQ:OLMA) 的 "买入" 评级，目标价为 30.00 美元。其他分析师也给出了评级，Oppenheimer 将其目标价下调至 25.00 美元，摩根大通则将其下调至 28.00 美元。Olema 的股票开盘价为 4.91 美元，市值为 3.3552 亿美元。该公司报告的季度每股收益为（0.51 美元），超出预期。机构投资者持有 91.78% 的股份，显示出机构对该公司的强烈兴趣</p>

<p>Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report)'s stock had its &#34;buy&#34; rating reissued by stock analysts at HC Wainwright in a report released on Monday,Benzinga reports. They currently have a $30.00 target price on the stock.</p>
<div class="lb-trans"><p>Olema Pharmaceuticals（纳斯达克代码：OLMA - 获取免费报告）的股票在周一发布的报告中被 HC Wainwright 的股票分析师重新给予了 “买入” 评级，Benzinga 报道。他们目前对该股票的目标价格为 30.00 美元。</p>
</div><p>Get <strong>Olema Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Olema Pharmaceuticals</strong> 的提醒：</p>
</div><p>A number of other analysts have also weighed in on OLMA. Oppenheimer reiterated an &#34;outperform&#34; rating and issued a $25.00 target price (down previously from $30.00) on shares of Olema Pharmaceuticals in a research note on Wednesday, March 19th. JPMorgan Chase &amp; Co. reduced their target price on shares of Olema Pharmaceuticals from $30.00 to $28.00 and set an &#34;overweight&#34; rating for the company in a report on Friday, March 28th.</p>
<div class="lb-trans"><p>其他一些分析师也对 OLMA 发表了看法。Oppenheimer 在 3 月 19 日的研究报告中重申了 “跑赢大盘” 的评级，并将 Olema Pharmaceuticals 的目标价格下调至 25.00 美元（之前为 30.00 美元）。摩根大通将 Olema Pharmaceuticals 的目标价格从 30.00 美元下调至 28.00 美元，并在 3 月 28 日的报告中对该公司设定了 “增持” 评级。</p>
</div><p><strong>Check Out Our Latest Analysis on OLMA</strong></p>
<div class="lb-trans"><p><strong>查看我们对 OLMA 的最新分析</strong></p>
</div><h2>Olema Pharmaceuticals Stock Down 3.7 %</h2>
<div class="lb-trans"><h2>Olema Pharmaceuticals 股票下跌 3.7%</h2>
</div><p>NASDAQ:OLMA opened at $4.91 on Monday. The company's 50 day moving average price is $4.20 and its 200-day moving average price is $6.78. Olema Pharmaceuticals has a 52 week low of $2.86 and a 52 week high of $16.62. The stock has a market cap of $335.52 million, a price-to-earnings ratio of -2.24 and a beta of 2.10.</p>
<div class="lb-trans"><p>纳斯达克：OLMA 周一开盘价为 4.91 美元。该公司的 50 日移动平均价格为 4.20 美元，200 日移动平均价格为 6.78 美元。Olema Pharmaceuticals 的 52 周最低价为 2.86 美元，52 周最高价为 16.62 美元。该股票的市值为 3.3552 亿美元，市盈率为-2.24，贝塔值为 2.10。</p>
</div><p>Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.63) by $0.12. As a group, sell-side analysts anticipate that Olema Pharmaceuticals will post -2.33 earnings per share for the current year.</p>
<div class="lb-trans"><p>Olema Pharmaceuticals（纳斯达克代码：OLMA - 获取免费报告）最近在 3 月 18 日发布了季度财报。该公司报告每股收益（EPS）为-0.51 美元，超出分析师一致预期的-0.63 美元，超出幅度为 0.12 美元。整体来看，卖方分析师预计 Olema Pharmaceuticals 在本年度将发布-2.33 美元的每股收益。</p>
</div><h2>Institutional Trading of Olema Pharmaceuticals</h2>
<div class="lb-trans"><h2>Olema Pharmaceuticals 的机构交易</h2>
</div><p>Institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase &amp; Co. lifted its position in Olema Pharmaceuticals by 658.7% in the third quarter. JPMorgan Chase &amp; Co. now owns 181,032 shares of the company's stock valued at $2,162,000 after acquiring an additional 157,171 shares during the last quarter. HighTower Advisors LLC acquired a new stake in shares of Olema Pharmaceuticals during the fourth quarter valued at $510,000. Hennion &amp; Walsh Asset Management Inc. lifted its stake in shares of Olema Pharmaceuticals by 80.5% during the fourth quarter. Hennion &amp; Walsh Asset Management Inc. now owns 212,246 shares of the company's stock valued at $1,237,000 after buying an additional 94,651 shares during the period. Alliancebernstein L.P. increased its stake in Olema Pharmaceuticals by 77.7% in the fourth quarter. Alliancebernstein L.P. now owns 313,982 shares of the company's stock valued at $1,831,000 after purchasing an additional 137,319 shares during the last quarter. Finally, Barclays PLC boosted its holdings in shares of Olema Pharmaceuticals by 105.0% in the 3rd quarter. Barclays PLC now owns 94,915 shares of the company's stock valued at $1,133,000 after purchasing an additional 48,614 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近增加或减少了对该股票的持股。摩根大通在第三季度将其在 Olema Pharmaceuticals 的持股比例提高了 658.7%。摩根大通目前拥有 181,032 股该公司的股票，价值 2,162,000 美元，此前在上个季度增持了 157,171 股。HighTower Advisors LLC 在第四季度收购了 Olema Pharmaceuticals 的新股份，价值 510,000 美元。Hennion &amp; Walsh 资产管理公司在第四季度将其在 Olema Pharmaceuticals 的持股比例提高了 80.5%。Hennion &amp; Walsh 资产管理公司目前拥有 212,246 股该公司的股票，价值 1,237,000 美元，此前在该期间增持了 94,651 股。Alliancebernstein L.P.在第四季度将其在 Olema Pharmaceuticals 的持股比例提高了 77.7%。Alliancebernstein L.P.目前拥有 313,982 股该公司的股票，价值 1,831,000 美元，此前在上个季度增持了 137,319 股。最后，巴克莱银行在第三季度将其在 Olema Pharmaceuticals 的持股比例提高了 105.0%。巴克莱银行目前拥有 94,915 股该公司的股票，价值 1,133,000 美元，此前在上个季度增持了 48,614 股。机构投资者和对冲基金持有该公司 91.78% 的股票。</p>
</div><h2>Olema Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Olema Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.</p>
<div class="lb-trans"><p>Olema Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，专注于女性癌症的治疗方法的发现、开发和商业化。其主要产品候选药物是 OP-1250，一种雌激素受体（ER）拮抗剂和选择性 ER 降解剂，目前正在进行针对复发性、局部晚期或转移性雌激素受体阳性、HER2 阴性乳腺癌的三期临床试验；以及 OP-1250 与 CDK4/6 抑制剂 palbociclib、ribociclib 和 alpelisib 联合进行的一期/二期临床试验，针对复发性、局部晚期或转移性雌激素受体阳性、HER2 阴性乳腺癌，同时开发 OPERA-01 用于 ER+/HER2-晚期或转移性乳腺癌的治疗。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Olema Pharmaceuticals</li>
<li>Most Volatile Stocks, What Investors Need to Know</li>
<li>The Bear Market Has Only Just Started - Here's Why</li>
<li>Using the MarketBeat Dividend Tax Calculator</li>
<li>These 3 ETFs Let You Hold Real Gold Without the Vault</li>
<li>How to Invest in Small Cap Stocks</li>
<li>Why Institutions Are Buying Super Micro Computer Stock Again</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Olema Pharmaceuticals 更好</li>
<li>最具波动性的股票，投资者需要知道的事项</li>
<li>熊市才刚刚开始 - 这是为什么</li>
<li>使用 MarketBeat 股息税计算器</li>
<li>这三只 ETF 让你在不需要金库的情况下持有真正的黄金</li>
<li>如何投资小盘股</li>
<li>为什么机构再次购买超微计算机股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Olema Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Olema Pharmaceuticals 吗？</h2>
</div><p>Before you consider Olema Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Olema Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Olema Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Olema Pharmaceuticals 并不在名单上。</p>
</div><p>While Olema Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Olema Pharmaceuticals 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

HC Wainwright 重申了对 Olema Pharmaceuticals（OLMA）的买入评级